A study by researchers at the University of Arizona College of Medicine – Tucson suggests that an FDA-approved osteoporosis treatment could help restore the shape of a mutated protein and enhance heart function.
A research team co-led by scientists from the University of Arizona College of Medicine – Tucson has discovered that an osteoporosis drug may counteract a rare genetic mutation linked to a specific form of heart disease. Their findings, published in the Journal of Clinical Investigation, could have broader implications for treating other rare diseases.
Dilated cardiomyopathy (DCM) is a group of disorders characterized by weakened heart muscles, which can lead to life-threatening complications as the heart struggles to pump blood efficiently. According to the American Heart Association, DCM primarily affects children and adults under 50…